1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Roche Prepares Faricimab For Filing After Phase III AMD Data

Non-Inferior To Eylea With Longer Dosing Intervals

 
• By Alexandra Shimmings

Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.    

Eye in an high tech environment
• Source: Shutterstock

Topline data from two Phase III trials in neovascular or ‘wet’ age-related macular degeneration (nAMD) show Roche Holding AG’s investigational bispecific antibody faricimab is as effective as – but no better than – Bayer AG and Regeneron Pharmaceuticals, Inc.’s Eylea when dosed at fixed intervals of up to every 16 weeks.

The data from the identical TENAYA and LUCERNE studies add to those already reported from two Phase III trials in diabetic macular edema – YOSEMITE and RHINE – just before Christmas

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D